14-day Premium Trial Subscription Sign Up For FreeGet Free

Clovis Oncology Stock Forecast NASDAQ:CLVS

Price Target and Analyst Ratings

Most Recent Rating

On August 05, 2021 "HC Wainwright" gave "$12.00 - $10.00" rating for CLVS. The price target was changed from $4.82 to 0.8%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-05 $12.00 - $10.00 Target Lowered by HC Wainwright $5.06 $4.82→0.8%
2021-05-11 Buy Target Lowered by HC Wainwright $5.61 $13.00 → $12.00
2021-05-05 Buy Target Lowered by HC Wainwright $5.86 $13.00 → $12.00
2021-02-23 Buy Target Lowered by HC Wainwright $6.01 $15.00 → $13.00
2021-01-14 Buy Reiterated by HC Wainwright $5.96 $15.00
2021-01-08 Buy Reiterated by HC Wainwright $5.05
2020-11-06 Buy Target Lowered by HC Wainwright $4.26 $23.00 → $15.00
2020-11-06 Underperform Target Lowered by SVB Leerink $4.26 $4.00 → $3.00
2020-11-05 Neutral Target Lowered by Piper Sandler $4.47 $6.00 → $5.00
2020-11-01 Hold Reiterated by JPMorgan Chase & Co. $4.93
2020-09-21 Buy Reiterated by HC Wainwright $7.07 $23.00
2020-09-03 Buy Reiterated by HC Wainwright $5.08
2020-08-06 Buy Reiterated by HC Wainwright $6.23
2020-05-20 Underperform Target Lowered by SVB Leerink $7.50 $5.00 → $4.00
2020-05-18 Buy Target Raised by HC Wainwright $8.96 $29.00 → $33.00
2020-05-06 Neutral Target Raised by Piper Sandler $8.07 $5.25 → $6.00
2020-05-06 Buy Target Raised by HC Wainwright $8.07 $27.00 → $29.00
2020-04-27 Market Perform - Underperform Downgraded by SVB Leerink $8.17 $5.00
2020-04-20 Buy Reiterated by Royal Bank of Canada $9.40 $17.00
2020-04-19 Neutral - Underperform Downgraded by Bank of America $8.16
2020-04-15 Buy Reiterated by HC Wainwright $7.21 $27.00
2020-04-09 Neutral - Underperform Downgraded by Bank of America $6.70 $6.00

CLVS Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -25.57% during the next 3 months and, with a 90% probability hold a price between $2.64 and $3.71 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $3.52 $4.24 $4.96
2021-09-21 $3.49 $4.21 $4.93
2021-09-22 $3.46 $4.18 $4.91
2021-09-23 $3.43 $4.16 $4.88
2021-09-24 $3.41 $4.13 $4.85
2021-09-27 $3.38 $4.10 $4.83
2021-09-28 $3.35 $4.08 $4.80
2021-09-29 $3.33 $4.05 $4.77
2021-09-30 $3.30 $4.02 $4.74
2021-10-01 $3.27 $3.99 $4.72
2021-10-04 $3.24 $3.97 $4.69
2021-10-05 $3.22 $3.94 $4.66
2021-10-06 $3.19 $3.91 $4.64
2021-10-07 $3.16 $3.88 $4.61
2021-10-08 $3.13 $3.86 $4.58
2021-10-11 $3.11 $3.83 $4.55
2021-10-12 $3.08 $3.80 $4.53
2021-10-13 $3.05 $3.78 $4.50
2021-10-14 $3.03 $3.75 $4.47
2021-10-15 $3.00 $3.72 $4.44
2021-10-18 $2.97 $3.69 $4.42
2021-10-19 $2.94 $3.67 $4.39
2021-10-20 $2.92 $3.64 $4.36
2021-10-21 $2.89 $3.61 $4.34
2021-10-22 $2.86 $3.59 $4.31
2021-10-25 $2.84 $3.56 $4.28
2021-10-26 $2.81 $3.53 $4.25
2021-10-27 $2.78 $3.50 $4.23
2021-10-28 $2.75 $3.48 $4.20
2021-10-29 $2.73 $3.45 $4.17

About Clovis Oncology

Clovis Oncology Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates, which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is under review with the U.S. and E.U. regulatory authorities for the treatment of non-small cell lung cancer; Rucapar... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT